L. 2004;202(1):10312. 29. Higgins S, et al. Fibroblast development factor 2 reactivates G1 checkpoint in SK-N-MC cells via regulation of p21, inhibitor of differentiation genes (Id1-3), and epithelium-mesenchyme transition-like events. Endocrinology. 2009;150(9):4044055. 30. Passiatore G, Gentilella A, Rom S, Pacifici M, Bergonzini V, Peruzzi F. Induction of Id-1 by FGF-2 requires activity of EGR-1 and sensitizes neuroblastoma cells to cell death. J Cell Physiol. 2011; 226(7):1763770. 31. Wang X, et al. Necessary role of ERK activation in neurite outgrowth induced by alpha-lipoic acid. Biochim Biophys Acta. 2011;1813(5):82738. 32. Qiao J, et al. PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys Res Commun. 2012;424(three):42126. 33. Andres JL, DeFalcis D, Noda M, Massague J. Binding of two development aspect families to separate domains on the proteoglycan betaglycan. J Biol Chem. 1992;267(9):5927930. 34. Sanchez NS, et al. The cytoplasmic domain of TGFbetaR3 via its interaction together with the scaffolding protein, GIPC, directs epicardial cell behavior. Dev Biol. 2011;358(two):33143. 35. Gatza CE, Oh SY, Blobe GC. Roles for the sort III TGF-beta receptor in human cancer. Cell Signal. 2010;22(8):1163174. 36. Oberthuer A, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma sufferers outperforms current clinical risk stratification. J Clin Oncol. 2006;24(31):5070078. 37. Wei JS, et al. Prediction of clinical outcome making use of gene expression profiling and artificial neural networks for sufferers with neuroblastoma. Cancer Res. 2004;64(19):6883891. 38. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with sophisticated disease stage. Science. 1984;224(4653):1121124. 39. Valentijn LJ, Koppen A, van Asperen R, Root HA, Haneveld F, Versteeg R. Inhibition of a brand new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes. Cancer Res. 2005;65(eight):3136145. 40. Kelsh RN. Sorting out Sox10 functions in neural crest development. Bioessays. 2006;28(8):78898. 41. Gershon TR, Oppenheimer O, Chin SS, Gerald WL. Temporally regulated neural crest transcription things distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia. 2005;7(6):57584. 42. Sato A, et al. FGF8 signaling is chemotactic for cardiac neural crest cells.Bovine Serum Albumin Dev Biol.Voriconazole 2011;354(1):180.PMID:32180353 43. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: principal adrenal tumor growth and spontaneous distant metastasis. In Vivo. 2002; 16(two):775. 44. Wesche J, Haglund K, Haugsten EM. Fibroblast development components and their receptors in cancer. Biochem J. 2011;437(two):19913. 45. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFRmediated carcinogenesis. Biochim Biophys Acta. 2012;1823(4):85060. 46. Kakodkar NC, et al. Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. 2012;59(four):64247. 47. Hahn CK, et al. Expression-based screening identifies the mixture of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008; 105(28):9751756. 48. Tsang KS, et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts making use of flow cytometry and reverse transcriptas.
HIV gp120-CD4 gp120-cd4.com
Just another WordPress site
